This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed Email this article to a friend

Biology of RANK, RANKL, and osteoprotegerin

Brendan F Boyce* and Lianping Xing

Arthritis Research & Therapy 2007, 9(Suppl 1):S1 doi:10.1186/ar2165

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive Arthritis Research & Therapy's emails?